Comparison 1 Probiotics versus control Outcome 15 Incidence CDAD 0-2 baseline risk RoB.Review Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children Comparison 1 Probiotics versus controlOutcome 15 Incidence CDAD 0-2 baseline risk RoBTotal events 16 Probiotics 22 ControlHeterogeneity Tau2  0.0 Chi2  0.08 df  2 P  0.96 I2 0.0 Test for overall effect Z  0.99 P  0.322 HighUnclearTotal events 8 Probiotics 9 ControlHeterogeneity Tau2  0.0 Chi2  4.16 df  6 P  0.65 I2 0.0 Test for overall effect Z  0.24 P  0.81Total 95 CI29682877100.0 0.77  0.45 1.32 Total events 24 Probiotics 31 ControlHeterogeneity Tau2  0.0 Chi2  4.36 df  9 P  0.89 I2 0.0 Test for overall effect Z  0.95 P  0.34Test for subgroup differences Chi2  0.12 df  1 P  0.73 I2 0.00.010.1110100Favours probioticsFavours controlProbiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children Review Copyright c 2017 The Cochrane Collaboration.

Comparison 1 Probiotics versus control Outcome 17 Incidence CDAD 5 baseline risk RoB.Review Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children Comparison 1 Probiotics versus controlOutcome 17 Incidence CDAD 5 baseline risk RoBTotal events 15 Experimental 47 ControlHeterogeneity Tau2  0.0 Chi2  2.21 df  4 P  0.70 I2 0.0 Test for overall effect Z  4.87 P  0.000012 UnclearHighTotal events 28 Experimental 79 ControlHeterogeneity Tau2  0.0 Chi2  2.37 df  7 P  0.94 I2 0.0 Test for overall effect Z  5.15 P  0.00001Total 95 CI13701084100.0 0.30  0.21 0.42 Total events 43 Experimental 126 ControlHeterogeneity Tau2  0.0 Chi2  5.14 df  12 P  0.95 I2 0.0 Test for overall effect Z  7.05 P  0.00001Test for subgroup differences Chi2  0.56 df  1 P  0.45 I2 0.00.010.1110100Favours probioticsFavours controlProbiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children Review Copyright c 2017 The Cochrane Collaboration.

Despite the need for further research hospitalized patients particularly those at high risk of CDAD should be informed of the potential benefits and harms of probiotics.S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N Probiotics compared to control for preventing C. difficile associated diarrheaPatient or population preventing C. difficile associated diarrheaSetting inpatient and outpatient Intervention probiotics Comparison controlOutcomesAnticipated absolute effects 95 CIRelative effect95 CIRisk with controlRisk with probioticsof participants studiesCertainty of the evi- denceGRADECommentsIncidence CDAD com - plete caseStudy populationRR 0.400.30 to 0.5240 per 100016 per 100012 to 21867231 RCTs0M ODERATE 1Note Risk with control calculated by pooled event rate across con- trol groupsCDAD baseline risk 0- 2Study populationRR 0.770.45 to 1.3211 per 10008 per 10005 to 14584515 RCTs0M ODERATE 2CDAD baseline risk 3- 5Study populationRR 0.530.16 to 1.7738 per 100020 per 10006 to 673733 RCTs00LOW 34CDAD baseline risk5Study populationRR 0.300.21 to 0.42116 per 100035 per 100024 to 49245413 RCTs0M ODERATE 5Incidence of C. diffi- cile inf ection com plete caseStudy populationRR 0.860.67 to 1.10121415 RCTs0M ODERATE 6170 per 1000147 per 1000114 to 187Adverse Events com - plete caseStudy populationRR 0.830.71 to 0.97170 per 1000141 per 1000121 to 165830532 RCTs000VERY LOW 789Incidence AAD com - plete caseStudy populationRR 0.580.48 to 0.70181 per 1000105 per 100087 to 127887033 RCTs00LOW 1011AAD AdultsStudy populationRR 0.620.51 to 0.76703623 RCTs00LOW 1213174 per 1000108 per 100089 to 133AAD ChildrenStudy populationRR 0.380.29 to 0.4911416 RCTs0M ODERATE 14271 per 1000103 per 100079 to 133Length of Hospital Stay com plete caseThe m ean length of Hospital Stay com - plete case was 0 daysM D 0.17 days f ewer 1.03 f ewer to 0.68 m ore-34844 RCTs0M ODERATE 15 The risk in the intervention group and its 95 conf idence interval is based on the assum ed risk in the com parison group and the relative effect of the intervention and its 95 CI.CI Conf idence interval RR Risk ratio OR Odds ratioGRADE Working Group grades of evidenceHigh certainty We are very conf ident that the true ef f ect lies close to that of the estim ate of the ef f ectM oderate certainty We are m oderately conf ident in the ef f ect estim ate The true ef f ect is likely to be close to the estim ate of the ef f ect but there is a possibility that it is substantially dif f erentLow certainty Our conf idence in the ef f ect estim ate is lim ited The true ef f ect m ay be substantially dif f erent f rom the estim ate of the ef f ect1 M uch of the data f or the overall ef f ect estim ate involves high baseline risk trials and theref ore we have concerns of indirectness at the population level when applying to m ore m oderate or lower baseline risk situations.2 Conf idence intervals are wide and cross the line of no ef f ect.3 Too f ew trials to conduct tests f or publication bias.4 Conf idence intervals are wide and cross the line of no ef f ect.5 Since there is som e residual uncertainty in our estim ate of ef f ect due to heterogeneity i.e.

Comparison 1 Probiotics versus control Outcome 47 Incidence AAD Child RoB.Review Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children Comparison 1 Probiotics versus controlOutcome 47 Incidence AAD Child RoBTotal events 14 Experimental 51 ControlHeterogeneity Tau2  0.0 Chi2  0.05 df  1 P  0.83 I2 0.0 Test for overall effect Z  4.48 P  0.00001Total 95 CI566575100.0 0.38  0.29 0.49 Total events 56 Experimental 156 ControlHeterogeneity Tau2  0.0 Chi2  2.31 df  5 P  0.80 I2 0.0 Test for overall effect Z  7.27 P  0.00001Test for subgroup differences Chi2  1.40 df  1 P  0.24 I2 290.010.1110100Favours probioticsFavours controlProbiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children Review Copyright c 2017 The Cochrane Collaboration.

The participants researchers and staff contributing to the study doctors nurses and microbiologists were unaware of the treatment allocations throughout the duration of the studyBlinding of participants and personnel performance biasAELow riskSee above Blinding of participants and per- sonnel performance bias CDADBlinding of participants and personnel performance biasAADLow riskSee above Blinding of participants and per- sonnel performance bias CDADBlinding of outcome assessment detection biasCDADLow riskThe participants researchers and staff contributing to the study doctors nurses and microbiologists were unaware of the treatment allocations throughout the dura- tion of the studyBlinding of outcome assessment detection biasAELow riskSee above Blinding of outcome assessment detection bias CDADPsaradellis 2010Risk of biasBiasAuthors' judgementSupport for judgementRandom sequence generation selection biasUnclear riskThe method of randomization was not de- scribedAllocation concealment selection biasUnclear riskNot enough information providedBlinding of participants and personnel performance biasCDADLow riskThis was a multicenter double-blind ran- domized placebo controlled study...Blinding of participants and personnel performance biasAELow riskSee above Blinding of participants and per- sonnel performance bias CDADBlinding of participants and personnel performance biasAADLow riskSee above Blinding of participants and per- sonnel performance bias CDADBlinding of outcome assessment detection biasCDADLow riskThere is no explicit mention of outcome assessor blinding.

Comparison 1 Probiotics versus control Outcome 13 Incidence CDAD Baseline Risk.Review Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children Comparison 1 Probiotics versus controlOutcome 13 Incidence CDAD Baseline RiskTotal events 24 Experimental 31 ControlHeterogeneity Tau2  0.0 Chi2  4.36 df  9 P  0.89 I2 0.0 Test for overall effect Z  0.95 P  0.343-5 Baseline riskHeterogeneity Tau2  0.0 Chi2  0.71 df  2 P  0.70 I2 0.0 Test for overall effect Z  1.04 P  0.300.010.1110100Favours probioticsFavours controlContinued .

Published by John Wiley  Sons Ltd.196LA  LC.Review Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children Comparison 1 Probiotics versus controlOutcome 44 Incidence AAD Species LGG versus LA  LCTotal events 91 Experimental 118 ControlHeterogeneity Tau2  0.03 Chi2  3.24 df  2 P  0.20 I2 38 Test for overall effect Z  3.26 P  0.0011Total 95 CI902821100.0 0.65  0.47 0.91 Total events 150 Experimental 191 ControlHeterogeneity Tau2  0.10 Chi2  13.94 df  6 P  0.03 I2 57 Test for overall effect Z  2.55 P  0.011Test for subgroup differences Chi2  0.43 df  1 P  0.51 I2 0.00.010.1110100Favours experimentalFavours controlProbiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children Review Copyright c 2017 The Cochrane Collaboration.

Comparison 1 Probiotics versus control Outcome 8 Incidence CDAD Subgroup Species all.Review Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children Comparison 1 Probiotics versus controlOutcome 8 Incidence CDAD Subgroup Species allTotal events 13 Experimental 32 ControlHeterogeneity Tau2  0.0 Chi2  4.18 df  6 P  0.65 I2 0.0 Test for overall effect Z  2.67 P  0.00762 S. cerevisiaeTotal events 12 Experimental 18 ControlHeterogeneity Tau2  0.0 Chi2  2.26 df  4 P  0.69 I2 0.00.0050.1110200Favours experimentalFavours controlContinued .

Comparison 1 Probiotics versus control Outcome 11 Incidence CDAD Subgroup Risk of Bias.Review Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children Comparison 1 Probiotics versus controlOutcome 11 Incidence CDAD Subgroup Risk of BiasTotal events 31 Experimental 71 ControlHeterogeneity Tau2  0.02 Chi2  8.42 df  8 P  0.39 I2 5 Test for overall effect Z  4.19 P  0.0000282 High or unclear risk of biasArvola 19991611581.0 0.95  0.06 14.85 Beausoleil 20071397421.8 0.15  0.02 1.19 Bravo 2008041041Not estimableCindoruk 2007059051Not estimableDuman 2005018511610.8 0.29  0.01 7.08 Fominykh 2013080040Not estimableLonnermark 20101760800.8 3.16  0.13 76.30 McFarland 19953804793.6 0.74  0.17 3.20 Miller 2008a4957945.4 0.57  0.17 1.87 Miller 2008b215601550.8 4.97  0.24 102.65 0.010.1110100Favours experimentalFavours controlContinued .

Comparison 1 Probiotics versus control Outcome 20 Incidence of infection Inpatient versus outpatient.Review Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children Comparison 1 Probiotics versus controlOutcome 20 Incidence of infection Inpatient versus outpatientStudy or subgroupExperimentalControlRisk RatioWeightRisk RatioHeterogeneity not applicableTest for overall effect Z  0.03 P  0.97nNnNM-HRandom95CIM-HRandom95CITotal 95 CI587545100.0 0.85  0.66 1.09 Total events 94 Experimental 97 ControlHeterogeneity Tau2  0.0 Chi2  5.59 df  10 P  0.85 I2 0.0 Test for overall effect Z  1.26 P  0.21Test for subgroup differences Chi2  1.13 df  2 P  0.57 I2 0.00.010.1110100Favours probioticsFavours controlAnalysis 1.21.

